 AUSTIN, Texas, Oct. 11, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in transforming care through genetic and cell-free DNA testing, today announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease MRD test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer CRC. The full study can be found here. 